Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why MiMedx Group Inc (MDXG) Shares Rebounded

Although we don’t believe in timing the market or panicking over market movements, we do like to keep an eye on big changes — just in case they’re material to our investing thesis.

What: Shares of MiMedx Group Inc (NASDAQ:MDXG), a manufacturer of patented regenerative biomaterial products, jumped as much as 22% today following yesterday’s mammoth 36% decline after holding a conference call to discuss the Food and Drug Administration’s untitled letter.

MiMedx Group Inc (NASDAQ:MDXG)

So what: If you recall, yesterday MiMedx Group Inc (NASDAQ:MDXG) announced the receipt of an untitled letter (i.e., an initial notification of violations from the FDA, but not meeting the threshold in severity of a warning letter) that because it uses a micronization process on select manufactured products, those products should, in turn, be treated as drugs. Since the FDA has not allocated the proper licenses to MiMedx Group Inc (NASDAQ:MDXG), it therefore could be manufacturing some of these products illegally.

Today, management reiterated its full-year 2013 and 2014 fiscal guidance, noting that the FDA’s untitled letter will not stop it from reaching its revenue targets and adamantly denied any wrongdoing with its manufacturing process. In fact, MiMedx Group Inc (NASDAQ:MDXG) points out that the FDA has examined the line of products in question and OK’d them from a safety perspective last year! With the expectation of a meeting shortly with the FDA and a resolution, MiMedx Group Inc (NASDAQ:MDXG) doesn’t anticipate any production interruptions.

Now what: As a shareholder, you have to be pleased with how quickly MiMedx’s management team has fired back at the FDA. On the other hand, there are still a lot of unanswered questions here, and there doesn’t seem to be much of a reason for the share price to head higher until they’re answered. Lawsuits are pouring in by the handful as well, which will only further complicate matters for MiMedx Group Inc (NASDAQ:MDXG). As I stated yesterday, the best course of action might be to just add MiMedx to your watchlist but avoid the stock altogether until we have better clarity.

The article Why MiMedx Group Shares Rebounded originally appeared on is written by Sean Williams.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.